Insurers weigh the short-term cost of GLP-1 therapies (up to ~$17K annually) against the long-term savings from reduced obesity-related complications
The results of our analysis confirm the lack of any benefit by DPP-4 inhibitors on cardiorenal outcomes in people with type 2 diabetes [22]
This can lead to increased energy levels, better digestion, and a stronger immune response.* Neutralization Of Free Radicals Free radicals are unstable molecules that can cause oxidative stress, leading to cellular damage and aging
00:12:02 Vickie Danaher So if you spot a patient on both, clarify the plan with the prescriber and make sure that only one GLP-1 therapy is being used at a time
Hydrating base (humectants like glycerin or similar, depending on formulation)
WEGOVY increased from 989 users in 2021 to 2,992 in 2022, while MOUNJARO reached 1,508 users in 2022